Article Information
History
- April 22, 2021.
Article Versions
- You are currently viewing Version 1 of this article (April 22, 2021 - 20:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jazmin Aguado-Sierra1,*,
- Constantine Butakoff2,
- Renee Brigham4,
- Apollo Baron2,
- Guillaume Houzeaux1,2,
- Jose M. Guerra3,
- Francesc Carreras3,
- David Filgueiras-Rama5,
- Paul A. Iaizzo4,
- Tinen L. Iles4 and
- Mariano Vazquez1,2
- 1Barcelona Supercomputing Center, Barcelona, Spain
- 2Elem Biotech S.L., Barcelona, Spain
- 3Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, CIBERCV, Barcelona, Spain
- 4Visible Heart® Laboratories, Department of Surgery and the Institute for Engineering in Medicine, University of Minnesota, Minneapolis, United States
- 5Fundación Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERCV, Madrid, Spain
- ↵*Corresponding author; email: jazmin.aguado{at}bsc.es
Posted April 22, 2021.
In-silico clinical trial using high performance computational modeling of a virtual human cardiac population to assess drug-induced arrhythmic risk
